A prospective, randomized, controlled, single blind clinical study of Shenqigui oral liquid for improving bone marrow suppression in patients with small cell lung cancer of Qi and yin defi
- Conditions
- Gas-yin two impeved small cell lung cancer
- Registration Number
- ITMCTR2100004677
- Lead Sponsor
- Chengdu University of Traditional Chinese Medicine
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Pending
- Sex
- All
- Target Recruitment
- Not specified
(1) Clinically, it is clearly diagnosed as a wide range of small cell lung cancer;
(2) Chinese medicine is divided into gas and yin;
(3) Popular semen of small cell lung cancer;
(4) Compliance with the joint chemotherapy standard, parallel cycle treatment;
(5) Age 18-75 years old, male or female;
(6) Agree to receive traditional Chinese medicine treatment;
(7) Informed consent and signed an informed consent book.
(1) Expected survival time <3 months;
(2) Merge hematopoietic dysfunction;
(3) Women within pregnancy or lactation;
(4) Severe mental illness;
(5) Accompanied by severe heart and brain, liver, kidney and other diseases;
(6) Unable to accept oral drug therapy;
(7) Kidney gas returning oral liquid and its ingredient allergic;
(8) Blood transfusion therapy;
(9) Simultaneous radiotherapy.
Study & Design
- Study Type
- Interventional study
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Bone marrow suppression degree leveling and incidence;
- Secondary Outcome Measures
Name Time Method TCM symptoms;Nausea and vomiting;Survival quality KPS rating;Quality Rating;